Ji Xuan

Ji Xuan


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2025 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
YQYuping Qiu
Yuping Qiu
SLShupei Li
Shupei Li
MJMingzuo Jiang
Mingzuo Jiang
AHAng Huang
Ang Huang
YYYa Yang
Ya Yang
JXJi Xuan
Ji Xuan
Background: Lang Qing A Ta (Huagan Tongluo Fang, HGTLF) is a Tibetan medicine with significant anti-liver fibrosis effects and good efficacy in the treatment of liver diseases, including non-alcoholic fatty liver disease (NAFLD). Quercetagetin (QG) has been identified as an active ingredient of HGTLF that is absorbed into the blood. This study aims to investigate the role of QG in the anti-liver fibrosis effect of HGTLF in NAFLD. Methods: CCl4 injection-induced liver fibrosis and high-fat, high-cholesterol diet-induced non-alcoholic steatohepatitis (NASH) mouse models were established. Transforming growth factor-β1 (TGF-β1)-induced hepatic stellate cells (HSCs) were used as in vitro models. The effect of QG on the stability and degradation pathway of glu-tathione peroxidase 4 (GPX4) protein was investigated. Results: QG improved liver function and hyperlipidemia in CCl4-injected mice and NASH mice, and alleviated hepatic lipid deposition and hepatic fibrosis. TGF-β1 treatment promoted the expression of α-smooth muscle actin and fibrosis-related genes, while QG reversed this phenomenon and inhibited HSC activation. QG increased the intracellular labile iron pool and lipid reactive oxygen species in HSCs. Treatment with the ferroptosis inhibitor ferrostatin-1 reversed the inhibitory effect of QG on TGF-β1-induced HSC activation. QG reduced GPX4 protein stability and regulated GPX4 K167 ubiquitination via the membrane-associated ring-CH-type finger 8 (MARCHF8)-mediated ubiquitin–proteasome pathway. Interference with MARCHF8 attenuated the effect of QG and promoted HSC activation induced by TGF-β1. Conclusion: QG, the active ingredient of HGTLF, can induce ferroptosis of HSCs by targeting the degradation of GPX4 through ubiquitination and inhibit HSC activation, thereby alleviating liver fibrosis in NAFLD.

1 March 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
SLShupei Li
Shupei Li
HZHanlong Zhu
Hanlong Zhu
QZQi Zhai
Qi Zhai
YHYu Hou
Yu Hou
YYYa Yang
Ya Yang
JXJi Xuan
Ji Xuan
Background: Non-alcoholic steatohepatitis (NASH), as a progressive form of Non-alcoholic fatty liver disease (NAFLD), poses a significant threat to human health as a prevalent and common condition, with a lack of safe and effective therapeutic options. However, the therapeutic effects and potential mechanisms of Lang Qing Ata (LQAtta) against NASH remain elusive. Materials and Methods: The components of LQAtta were identified using Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry (UHPLC-MS/MS). Subsequently, we employed network construction and analysis approaches within the field of network pharmacology. By integrating known databases and target prediction algorithms, which encompassed database-based target prediction, protein-protein interaction networks, as well as Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, we unveiled the potential key targets and signaling pathways that these bioactive components might engage with. These discoveries were further validated in subsequent mouse models. An HFHC-induced NASH mouse model was used to validate the therapeutic effects and potential mechanisms of LQAtta on NASH. Results: From the UHPLC-MS/MS analysis of LQAtta, a total of 1518 chemical components were identified, with 106 of them being absorbed into the bloodstream. Additionally, based on the acquisition of targets from both LQAtta and the NASH database, a total of 160 common targets were screened. KEGG enrichment analysis indicated that LQAtta may alleviate NASH by modulating pathways such as the Toll-like receptor signaling pathway, the NF-κB signaling pathway, and inflammation-related pathways. In vivo experimental results demonstrated that LQAtta could alleviate liver injury, steatosis, and inflammation induced by NASH, thereby slowing down the disease process. Additionally, LQAtta inhibited the expression and phosphorylation of NF-κB protein, playing a role in preventing NASH. Conclusion: In this study, the combination of mass spectrometry analysis, network pharmacology, and animal experiments preliminarily elucidated the potential of LQAtta to treat NASH through NF-κB pathways.

23 October 2025 in European Journal of Pharmacology
Verified
Journal Article
Closed access
XCXi Chen
Xi Chen
YYYeqing Yu
Yeqing Yu
XXXiangxiang Xu
Xiangxiang Xu
HLHaifeng Lan
Haifeng Lan
JLJiaxin Li
Jiaxin Li
HLHui Li
Hui Li

2 July 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
HLHaifeng Lan
Haifeng Lan
MLMengjie Lu
Mengjie Lu
SLShupei Li
Shupei Li
MSMei Shao
Mei Shao
YYYa Yang
Ya Yang
JXJi Xuan
Ji Xuan
There was a mistake in Table 2 as published. In the original Table 2, the confidence intervals for adjusted risk ratios were calculated using the Wald method, and the Pvalues were derived from Wald tests. Given our limited sample size, binary outcomes, and adjustment for multiple covariates, this approximation was imprecise,leading to logical inconsistencies in the Adjusted RR (95% CI) and Pvalue columns (e.g., confidence intervals that excluded 1 but P-values > 0.05). The corrected Table 2

10 March 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
HLHaifeng Lan
Haifeng Lan
MLMengjie Lu
Mengjie Lu
SLShupei Li
Shupei Li
MSMei Shao
Mei Shao
YYYa Yang
Ya Yang
JXJi Xuan
Ji Xuan
Objective: High-quality bowel preparation is essential for accurate colonoscopy. Currently, linaclotide is used as an adjunctive agent supporting bowel preparation, but evidence for its combination with oral sulfate solution (OSS) remains limited. This study aimed to evaluate whether the addition of linaclotide to OSS could improve the efficacy of bowel preparation. Methods: This single-blind, randomized controlled trial enrolled outpatients scheduled for colonoscopy. Participants were randomly assigned (1:1:1) to one of three groups: the OSS + Linaclotide group, the OSS group, or the polyethylene glycol (PEG) group. The primary outcome was the adequate bowel preparation rate, while secondary outcomes included tolerability, colonoscopy findings, and safety. Efficacy endpoints were assessed in the modified intention-to-treat (mITT) population, and safety was evaluated in the as-treated population. Results: A total of 370 patients were included in the mITT analysis. There was no statistically significant difference in the adequate bowel preparation rate between the OSS + Linaclotide group and the OSS group (86.5% vs. 88.0%; unadjusted relative risk [RR], 0.98; 95% confidence interval [CI], 0.89–1.08; p = 0.723). In the unadjusted analysis, both the OSS + Linaclotide group (86.5% vs. 73.9%; unadjusted RR, 1.17; 95% CI, 1.03–1.33; p = 0.013) and the OSS group (88.0% vs. 73.9%; unadjusted RR, 1.19; 95% CI, 1.05–1.35; p = 0.005) demonstrated significantly higher adequate bowel preparation rates than the PEG group. Moreover, the analysis adjusted for covariates showed no statistically significant differences between groups ( p > 0.05). In exploratory analysis, patient-reported incidence of bloating was less frequent in the OSS + Linaclotide group (4.0% vs. 16.0% vs. 11.8%, p = 0.007), with no increase in nausea, vomiting, or other adverse events. No significant between-group differences were observed in other tolerability measures or colonoscopy findings. Conclusion: This study did not meet its primary endpoint. Linaclotide added to OSS provided no additional cleansing efficacy over OSS alone or PEG. Exploratory analysis found that the combination may reduce bloating, a potential tolerability advantage requiring further verification in future studies.

8 January 2026 in Endoscopy
Verified
Journal Article
Open access
PDF file
CSChangqing Sun
Changqing Sun
JWJuan Wei
Juan Wei
YQYuping Qiu
Yuping Qiu
SLShupei Li
Shupei Li
JXJuan Xu
Juan Xu
JXJi Xuan
Ji Xuan
10.1055/a-2589-0790 In the above-mentioned article affiliation 1 has been corrected. This was corrected in the online version on March 13, 2026. Article published online: 13 March 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany